Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Dec 5, 2023
- Accession no.
- 0001447362-23-000165
- Filed
- Dec 5, 2023
- Trade date
- Dec 1-4, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 14 non-derivative transactions. Open-market sales total $193.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2023 | Common Stock | SSaleDisposed | −3,235 | $20.06F2 | −$64,894.1 | 98,644 | Direct | |
| Dec 1, 2023 | Common Stock | SSaleDisposed | −1,020 | $20.06F2 | −$20,461.2 | 100,664 | Indirect | |
| Dec 1, 2023 | Common Stock | SSaleDisposed | −1,020 | $20.06F2 | −$20,461.2 | 89,559 | Indirect | |
| Dec 1, 2023 | Common Stock | SSaleDisposed | −373 | $20.06F2 | −$7,482.38 | 14,759 | Indirect | |
| Dec 1, 2023 | Common Stock | SSaleDisposed | −371 | $20.06F2 | −$7,442.26 | 14,762 | Indirect | |
| Dec 1, 2023 | Common Stock | SSaleDisposed | −371 | $20.06F2 | −$7,442.26 | 14,763 | Indirect | |
| Dec 1, 2023 | Common Stock | SSaleDisposed | −371 | $20.06F2 | −$7,442.26 | 14,756 | Indirect | |
| Dec 4, 2023 | Common Stock | SSaleDisposed | −1,379 | $20.08F9 | −$27,690.32 | 97,265 | Direct | |
| Dec 4, 2023 | Common Stock | SSaleDisposed | −435 | $20.08F9 | −$8,734.8 | 100,229 | Indirect | |
| Dec 4, 2023 | Common Stock | SSaleDisposed | −435 | $20.08F9 | −$8,734.8 | 89,124 | Indirect | |
| Dec 4, 2023 | Common Stock | SSaleDisposed | −157 | $20.08F9 | −$3,152.56 | 14,602 | Indirect | |
| Dec 4, 2023 | Common Stock | SSaleDisposed | −159 | $20.08F9 | −$3,192.72 | 14,603 | Indirect | |
| Dec 4, 2023 | Common Stock | SSaleDisposed | −159 | $20.08F9 | −$3,192.72 | 14,604 | Indirect | |
| Dec 4, 2023 | Common Stock | SSaleDisposed | −159 | $20.08F9 | −$3,192.72 | 14,597 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.23, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $20.00 to $20.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.